Dianthus Therapeutics Executive Compensation (FY25)
DNTH · Executive and director compensation, fiscal 2024 to 2025
The Dianthus Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 20, 2026Latest filing (8-K): May 22, 2026
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
111 figures on this page: 108 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Marino Garcia: $8,843,300 → $10,614,702 (20.0% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Dianthus Therapeutics' chief executive and what were they paid?
Marino Garcia, Director, President and Chief Executive Officer, received $10,614,702 in total compensation for fiscal 2025. Compared with the $8,843,300 reported for fiscal 2024, Garcia's total was 20.0% higher.
What was Dianthus Therapeutics' say-on-pay result?
The say-on-pay proposal drew 96.0% of votes cast for or against in favor at the meeting held May 21, 2026 for fiscal 2025.
Which companies are in Dianthus Therapeutics' peer group?
The disclosed peer group includes 4D Molecular Therapeutics, Inc., Anaptysbio, Inc, Annexon, Inc., Apogee Therapeutics, Inc. and Astria Therapeutics, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Marino Garcia Director, President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Simrat Randhawa Executive Vice President, Head of Research and Development | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Ryan Savitz Executive Vice President, Chief Financial Officer, Chief Business Officer and Treasurer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Marino Garcia Director, President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Simrat Randhawa Executive Vice President, Head of Research and Development | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Ryan Savitz Executive Vice President, Chief Financial Officer, Chief Business Officer and Treasurer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Simrat Randhawa | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Ryan Savitz | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Marino Garcia | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Sujay Kango | ◇ | — | ◇ | — | — | — | ◇ |
Simon Read, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Simon Read | ◇ | — | ◇ | — | — | — | ◇ |
Alison F. Lawton | ◇ | — | ◇ | — | — | — | ◇ |
Anne McGeorge | ◇ | — | ◇ | — | — | — | ◇ |
Paula Soteropoulos | ◇ | — | ◇ | — | — | — | ◇ |
Steven Romano, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Jonathan Violin | ◇ | — | ◇ | — | — | — | ◇ |
Jonathan Violin, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Leon O. Moulder Jr | ◇ | — | — | — | — | — | ◇ |
Tomas Kiselak | ◇ | — | — | — | — | — | ◇ |
Marino Garcia served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 4D Molecular Therapeutics, Inc. FDMT
- Anaptysbio, Inc ANAB
- Annexon, Inc. ANNX
- Apogee Therapeutics, Inc. APGE
- Astria Therapeutics, Inc. ATXS
- Aura Biosciences, Inc. AURA
- Cabaletta Bio, Inc. CABA
- Disc Medicine, Inc. IRON
- Dyne Therapeutics, Inc. DYN
- Edgewise Therapeutics, Inc. EWTX
- Inozyme Pharma, Inc. INZY
- Kymera Therapeutics, Inc. KYMR
- Kyverna Therapeutics, Inc. KYTX
- Longboard Pharmaceuticals, Inc. LBPH
- Pepgen Inc. PEPG
- Spyre Therapeutics, Inc. SYRE
- Stoke Therapeutics, Inc. STOK
- Structure Therapeutics Inc. GPCR
- Vera Therapeutics, Inc. VERA
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 21, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 22, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 23, 2024 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Dianthus Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Dianthus Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
111 figures on this page: 108 cited to the filing that reported them, 3 calculated from figures it prints.
108 cited to the filing
3 calculated from the filing
Documents cited
- 0001690585-26-000026Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001690585-26-000012DIRECTOR COMPENSATION
- 0000950170-25-076304Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-24-065371Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Dianthus Therapeutics executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/DNTH (accessed 2026).
Short form: data: Velarion
The Dianthus Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Dianthus Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Dianthus Therapeutics discloses
The companies named in DNTH's own disclosed peer group.
4D Molecular Therapeutics, Inc.Anaptysbio, IncAnnexon, Inc.Apogee Therapeutics, Inc.Astria Therapeutics, Inc.Aura Biosciences, Inc.Cabaletta Bio, Inc.Disc Medicine, Inc.Dyne Therapeutics, Inc.Edgewise Therapeutics, Inc.Inozyme Pharma, Inc.Kymera Therapeutics, Inc.Kyverna Therapeutics, Inc.Longboard Pharmaceuticals, Inc.Spyre Therapeutics, Inc.Stoke Therapeutics, Inc.Structure Therapeutics Inc.Vera Therapeutics, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}